PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Acceleron Pharma Inc.

USPTO PatentsView assignee record — 124 granted patents across 9 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).

Explore the portfolio See the ranking
124
Total patents granted
9
CPC technology areas
20.0
Avg claims per patent
+53%
5-year filing velocity

The verdict

Acceleron holds 124 US patents across 9 technology areas — rank #3,056 of 50,000 tracked assignees.

#3,056
of 50,000 US assignees by volume
Top 30%
by Innovation Score (42.6/100)
20.0
avg claims per patent
+53%
filing velocity, last 5 yrs

Portfolio overview

Acceleron Pharma Inc. has been granted 124 US utility patents between 2015 and 2025, placing Acceleron Pharma Inc. at rank #3,056 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.0 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, Acceleron Pharma Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 42.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 75 grants, compared with 49 in the 2015–2019 window — a +53% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Acceleron Pharma Inc.'s 20.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Acceleron Pharma Inc. against peers pursuing similar technology classes.

How does Acceleron compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Acceleron holds 124 patents — placing it at rank #3,056 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Acceleron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

051015202530 20152016201720182019202020212022202320242025 8
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Acceleron Pharma Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 4.0%
2016 10 8.1%
2017 7 5.6%
2018 12 9.7%
2019 15 12.1%
2020 13 10.5%
2021 27 21.8%
2022 10 8.1%
2023 6 4.8%
2024 11 8.9%
2025 8 6.5%

Which technologies does Acceleron Pharma Inc. patent most?

Top 9 of 9 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#3,056

Across all tracked assignees

Innovation Score

42.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Acceleron Pharma Inc. hold?
Acceleron Pharma Inc. holds 124 US granted patents filed between 2015 and 2025, spanning 9 technology areas.
What is Acceleron Pharma Inc.'s Innovation Score?
Acceleron Pharma Inc. has an Innovation Score of 42.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Acceleron Pharma Inc. focus on?
Acceleron Pharma Inc.'s top technology area is C07K (PEPTIDES) with 119 patents. The company has filed patents in 9 CPC subclasses total.
Is Acceleron Pharma Inc.'s patent filing rate increasing or decreasing?
Acceleron Pharma Inc.'s recent filing velocity is +53% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Acceleron Pharma Inc.'s patents?
Acceleron Pharma Inc.'s patents average 20.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Acceleron Pharma Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

Explore the patent dataset

C07K technology

Acceleron Pharma Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders

See where Acceleron Pharma Inc. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope